





Risk Based Approach to Software Quality and Validation

© Copyright 2025 by ProPharma Group. All rights reserved. No part of these materials may be reproduced or transmitted in any form without the written permission of ProPharma Group.

 v 25.10

1


Your Presenter

- Debra Bartel, MBA, CQA, PMP
- SVP, Quality Assurance
- 30 years experience specializing in software quality assurance, validation and regulatory compliance, Information Systems project management, and process design.
- Previously held management positions in the pharmaceutical industry in both Quality Assurance and Information Systems organizations
- Active member of American Society for Quality (ASQ), Northeastern Illinois Section, Software Division


 Validation Center™

Copyright © 2025, ProPharma Group 2

2



3



4

Have you ever heard...



- Computer System Validation is a waste of time
- It's just a bunch of paperwork
- It doesn't find the bugs
- We just repeated everything the vendor already did

VC Validation Center™ Copyright © 2025, ProPharma Group 5


5

Webinar Outline

- 1 • Validation & Risk Framework
- 2 • Risk Assessment
- 3 • Risk Mitigation
- 4 • FDA Leadership by Example

VC Validation Center™ Copyright © 2025, ProPharma Group 6

6



7


Part 1: Validation & Risk Framework

- Section Overview
 - Validation Terminology
 - Validation Process
 - Validation Roles & Responsibilities
 - Risk Terminology
 - Risk Process

Validation Center™ Copyright © 2025, ProPharma Group 8


8

Terminology




9

Validation Life Cycle




GENERAL APPROACH

10




11



12

Validation Life Cycle



13


Validation Roles



- Manages the business process that uses the computer system
- Ensures that the system is appropriate for the business process
- Assigns Subject Matter Experts (SMEs) to participate in requirements definition and verification


14

Validation Roles



15

Validation Roles



16

Basic Risk Terminology

Hazard

A potential source of harm



Validation Center™

Copyright © 2025, ProPharma Group



17

17

Basic Risk Terminology

Hazard

A potential source of harm

Risk

The combination of the probability of occurrence of a harm and the severity of the harm



Validation Center™

Copyright © 2025, ProPharma Group



18

18

Basic Risk Terminology

Hazard

A potential source of harm

Risk

Harm severity and probability

Risk Assessment

A comprehensive evaluation of risks and associated impacts

Severity:



19

Basic Risk Terminology

Hazard

A potential source of harm


Risk

Harm severity and probability

Risk Assessment

A comprehensive evaluation of risks and associated impacts

Probability:



20

Basic Risk Terminology

Hazard

A potential source of harm

Risk

Harm severity and probability

Risk Assessment Evaluation of risk and impact

Risk Mitigation

Actions taken to reduce the risk



Validation Center™

Copyright © 2025, ProPharma Group



21

21

Basic Risk Terminology

Hazard

A potential source of harm

Risk

Harm severity and probability

Risk Assessment Evaluation of risk and impact

Risk Mitigation Action to reduce impact

Risk Management

A systematic approach to assessment and mitigation of risks throughout the system life cycle



Validation Center™


Copyright © 2025, ProPharma Group



22

22

Risk Management Framework




VC Validation Center™

Copyright © 2025, ProPharma Group

23

23



Risk Assessment

Part 2

VC Validation Center™

Copyright © 2025, ProPharma Group

24

24

Part 2: Risk Assessment

- Section Overview
 - Regulatory Guidance
 - Risk Assessment Process
 - Documentation




Validation Center™

Copyright © 2025, ProPharma Group

25

25

USA



FDA Glossary of Computerized System and Software Development Terminology

Risk = A measure of the probability and severity of undesired effects. Often taken as the simple product of probability and consequence. (Source: IEEE)

Risk Assessment = A comprehensive evaluation of the **risk** and its associated impact (Source: DOD).

FDA 21 CFR 820 Quality System Regulation (Medical Device GMP)

- Design validation shall include software validation and **risk analysis**, where appropriate.

FDA Guidance: Off-The-Shelf Software Use in Medical Devices

- Existing international standards indicate that the estimation of **risk** should be considered as the product of the severity of harm and the probability of occurrence of harm.
- It is more appropriate to manage **software safety risk** based on the **severity of harm** rather than the **software failure rates**



Validation Center™

Copyright © 2025, ProPharma Group

26

26

ICH



ICH Q9, Quality Risk Management

Risk assessment consists of the identification of hazards and the analysis and evaluation of **risks** associated with exposure to those hazards.


Three fundamental questions:

1. What might go wrong?
2. What is the likelihood (probability) it will go wrong?
3. What are the consequences (severity)?

Validation Center™ Copyright © 2025, ProPharma Group 27

27

PIC/S



Members (red circle)
Applicants (green circle)

Members: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chinese Taipei, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Iceland, Indonesia, Iran, Ireland, Israel, Italy, Japan, Korea, Rep. of, Latvia

Applicants: Liechtenstein, Lithuania, Malaysia, Malta, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Saudi Arabia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Thailand, Turkey, Ukraine, United Kingdom, USA

Validation Center™ Copyright © 2025, ProPharma Group 28

28

PIC/S

- Argentina
- Australia
- Austria
- Belgium
- Canada
- Cyprus
- Czech
- Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Indonesia
- Ireland
- Israel
- Italy
- Japan
- Korea
- Latvia
- Liechtenstein
- Lithuania
- Malaysia
- Malta
- Netherlands
- New Zealand

PIC/S

PIC/S PI 011 *Good Practices for Computerised Systems Used in Regulated "GXP" Environments*

Risk Assessment

Regulated users should be able to justify and defend their standards, protocols, acceptance criteria, procedures, and records in the light of their own **documented risk and complexity assessments**.

The risk assessment and the results including the reasons for the ranking as either: 'critical' or 'not critical' should be documented.

The URS (User Requirements Specs) should form the basis of a risk assessment of the system for GxP compliance requirements, in addition to other risks, such as safety. The risk analysis may be based on the FS (Functional Spec), which is related to the URS.

The **risk assessment** should identify **critical** features

PIC/S

PIC/S PI 011 *Good Practices for Computerised Systems Used in Regulated "GXP" Environments*

Continued

- Norway
- Poland
- Portugal
- Romania
- Singapore
- Slovak
- Republic
- Slovenia
- South Africa
- Spain
- Sweden
- Switzerland
- Taiwan
- Ukraine
- United Kingdom
- USA

Validation Center™

Copyright © 2025, ProPharma Group

29

29

PIC/S

- Argentina
- Australia
- Austria
- Belgium
- Canada
- Cyprus
- Czech
- Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Indonesia
- Ireland
- Israel
- Italy
- Japan
- Korea
- Latvia
- Liechtenstein
- Lithuania
- Malaysia
- Malta
- Netherlands
- New Zealand

PIC/S

PIC/S PI 011 *Good Practices for Computerised Systems Used in Regulated "GXP" Environments*

Validation Scope & Approach

It is important to acknowledge that the scope and level of documentation and records needed to formalize and satisfy basic project management requirements for **critical** systems will be dependent on:

- The **complexity** of the system and variables
- The need to ensure data integrity
- The level of **risk** associated with its operation
- The GxP areas impacted

PIC/S

PIC/S PI 011 *Good Practices for Computerised Systems Used in Regulated "GXP" Environments*

Continued

- Norway
- Poland
- Portugal
- Romania
- Singapore
- Slovak
- Republic
- Slovenia
- South Africa
- Spain
- Sweden
- Switzerland
- Taiwan
- Ukraine
- United Kingdom
- USA


Validation Center™

Copyright © 2025, ProPharma Group

30

30

Risk Management Framework




31

Risk Assessment Roles




32

When does risk assessment take place?




33


When does risk assessment take place?



34




35




36

Example System



37

Example Hazards



What might go wrong?

User Requirement	Identified Hazard
1. Send test instructions to lab instruments and receive test result data from the instrument	An instrument interface problem could result in an incorrect reading from equipment
2. Calculate whether a test passes or fails using input from the lab instruments and analyst entries	An incorrect laboratory calculation could provide a passing test result when it should have failed
3. Assign analysts to perform tests based on training	A data integrity error in the training module could show that a lab analyst was trained when she was not
4. Calculate the charges for testing for each product line	There could be a calculation error in the Test Charge module

38

Hazard Evaluation

Evaluation

How are hazards evaluated?

□ Key Questions

- What are the consequences (severity) of the hazard?
- What is the likelihood (probability) the hazard will occur?

□ Areas of focus

- Features or functions that could lead to
 - Patient death or injury
 - Product failure or quality issue
 - Study outcomes
 - Compromised integrity of the associated data



Validation Center™

Copyright © 2025, ProPharma Group

39

39

Hazard Evaluation

Evaluation

How are hazards evaluated?

Risk Definition

The combination of the probability of occurrence of a hazard and the severity of the hazard

Risk Component 1

Severity of Harm

Measured as
Criticality

Risk Component 2

Probability of Occurrence

Measured as
Complexity



Validation Center™

Copyright © 2025, ProPharma Group

40

40

Hazard Evaluation

Severity
Evaluation

How are hazards evaluated?

Risk Definition

The combination of the probability of occurrence of a hazard and the severity of the hazard

Risk Component 1

Severity of Harm

Measured as
Criticality

Risk Component 2

Probability of Occurrence

Measured as
Complexity



Validation Center™

Copyright © 2025, ProPharma Group

41

41

Hazard Evaluation Examples

Severity
Evaluation

How are hazards evaluated?

URS	Identified Hazard	Evaluation of Severity
1	An instrument interface problem could result in an incorrect reading from equipment	Could result in an impure batch of product
2	An incorrect laboratory calculation could provide a passing test result when it should have failed	Could result in harm to a patient (if too potent) or failure to cure a patient (if not potent enough)
3	A data integrity error in the training module could show that a lab analyst was trained when she was not	Could result in a lab analyst being assigned to run a lab test without proper training
4	There could be a calculation error in the Test Charge module	Could result in a manufacturing department being overcharged



Validation Center™

Copyright © 2025, ProPharma Group

42

42

Severity Classification

Severity Classification

How is severity classified?

Common Classification Method

- Classification by Criticality
- 3 Levels

High Criticality	<u>Direct</u> impact on patient safety, product quality, study outcome, or the integrity of associated data
Medium Criticality	<u>Indirect</u> impact on patient safety, product quality, study outcome, or the integrity of associated data
Low Criticality	<u>No</u> impact on patient safety, product quality, study outcome, or the integrity of associated data



Validation Center™

Copyright © 2025, ProPharma Group

43

43

Severity Classification

Level	Expanded Definition
High Criticality	Direct control of: • Manufacturing • Labeling • Distribution • Product Testing • Product Release • Clinical Trials Direct impact on: • Product Quality • Patient Safety • Study Outcomes
Medium Criticality	Indirect impact on patient safety, product quality, study outcomes, or the integrity of associated data
Low Criticality	No impact on patient safety, product quality, study outcomes, or the integrity of associated data

Examples

- Health product software
- Manufacturing controls
- Automated product inspection
- Label management & automation
- Distribution tracking to enable recalls
- Laboratory test results
- Adverse event tracking
- Clinical trial results
- Patient medical records
- GCP EDC Records



Validation Center™

Copyright © 2025, ProPharma Group

44

44

Severity Classification

Level	Expanded Definition
High Criticality	Direct impact on patient safety, product quality, study outcomes, or the integrity of associated data
Medium Criticality	Indirect involvement in: •Manufacturing •Labeling •Distribution •Product Testing & Release •Clinical Trials Indirect impact on: •Product Quality •Patient Safety •Study Outcomes Provides GxP compliance for features not already identified as "High Criticality"
Low Criticality	No impact on patient safety, product quality, study outcomes, or the integrity of associated data

Examples

- Calibration tracking
- Validation tracking
- Training tracking
- Corrective/Preventive action tracking
- System access tracking
- Electronic submissions to regulatory agencies
- Product work order management
- Deviation tracking
- Audit tracking
- Approved Supplier Tracking
- eTMF records

Validation Center™
Copyright © 2025, ProPharma Group
45

45

Severity Classification

Level	Expanded Definition
High Criticality	Direct impact on patient safety, product quality, study outcomes, or the integrity of associated data
Medium Criticality	Indirect impact on patient safety, product quality, study outcomes, or the integrity of associated data
Low Criticality	Any function not already identified as "High Criticality" or "Medium Criticality"

Examples

- Manufacturing cost reports
- Turnaround time reports
- Automated reminders to approve documents

Validation Center™
Copyright © 2025, ProPharma Group
46

46

Severity Classification Examples

Severity Classification



URS	Identified Hazard	Evaluation of Severity	Criticality
1	An instrument interface problem could result in an incorrect reading from equipment	Could result in an impure batch of product	High
2	An incorrect laboratory calculation could provide a passing test result when it should have failed	Could result in harm to a patient or failure to cure a patient	High
3	A data integrity error in the training module could show that a lab analyst was trained when she was not	Could result in a lab analyst being assigned to run a lab test without proper training	Medium
4	There could be a calculation error in the Test Charge module	Could result in a manufacturing department being overcharged	Low

VC

Validation Center™

Copyright © 2025, ProPharma Group

47

47

Probability Evaluation

Probability Evaluation

How are hazards evaluated?

Risk Definition

The combination of the probability of occurrence of a hazard and the severity of the hazard

Risk Component 1

Severity of Harm

Measured as
Criticality

Risk Component 2

Probability of Occurrence

Measured as
Complexity

VC

Validation Center™

Copyright © 2025, ProPharma Group

48

48

Probability Assessed as “Complexity”



The selection of **validation activities** should be commensurate with the **complexity** of the software and the **risk** associated with use of the software for its specific intended use



Validation **coverage** should be based on the software's **complexity** and safety **risk**.



The scope and level of **documentation** and **records** needed to formalize and satisfy basic project management requirements for **critical** systems will be dependent on the **complexity** of the system.



Validation Center™

Copyright © 2025, ProPharma Group

49

49

Probability Classification

**Probability
Classification**

How can probability be classified?

Validation Approach	Complexity Level	Definition
	Low	Standard, non-configured functions within off-the-shelf purchased systems
	Medium	Configured functions within off-the-shelf purchased systems
	High	Custom developed functions within either purchased or custom systems



Validation Center™

Copyright © 2025, ProPharma Group

50


50

Probability Classification

Complexity Level	Definition	Examples
Low	Standard, non-configured functions within off-the-shelf purchased systems	- Standard test result report within an off-the-shelf laboratory system - Standard data entry screen in a medical records system
Medium	Configured functions within off-the-shelf purchased systems	- Report configured with an off-the-shelf query tool - Calculation configured in a laboratory system - Calculation configured in an off-the-shelf spreadsheet tool - Product release algorithm configured in an off-the-shelf inventory control system
High	Custom developed functions within either purchased or custom systems	- Custom accounting report developed in COBOL - Custom code developed to send e-mail notification from an off-the-shelf training management system

51

Probability Classification Example



52

Probability Classification Example

Probability Classification



URS	Requirement	Criticality	Technology	Complexity
1	Send test instructions to lab instruments and receive test result data from the instrument	High	Configured using the out-of-the-box instrument interface tool	Medium
2	Calculate whether a test passes or fails using input from the lab instruments and analyst entries	High	Custom code	High
3	Assign analysts to perform tests based on training	Medium	Out-of the box functionality	Low
4	Calculate the charges for testing for each product line	Low	Custom report developed in house	High



Validation Center™

Copyright © 2025, ProPharma Group

53

53

Classification Levels

Classification



	Requirement Level Criticality	Requirement Level Complexity
1	High	Medium
2	High	High
3	Medium	Low
4	Low	High

System level criticality is the same as the highest requirement level criticality

System Level Criticality

High



Validation Center™


Copyright © 2025, ProPharma Group

54

54

Risk Assessment Documentation

Where should the risk assessment be documented?



System Level

- Validation Master Plan (VMP)
- Stand-alone, Risk Assessment



Requirement Level

- Requirements Specification
- Stand-alone, Risk Assessment

options

55

Risk Assessment Documentation

System and Requirement Risk Assessment

System Name ABC Laboratory Management System
System Version 1.0

System Criticality Level ☒ High ☐ Medium ☐ Low


System Criticality Rationale System performs functions that are critical to patient safety. See details in the analysis, below.

Requirement Criticality and Complexity Analysis				
Requirement	Criticality Level	Rationale for Criticality Level	Complexity Level	Rationale for Complexity Level
Instrument control [URS 1]	High	An incorrect lab instrument reading could result in an impure batch of product.	Medium	Configured with system's instrument interface tool
Test pass/fail determination [URS 2]	High	A calculation error could result in patient harm or failure to cure a patient.	High	Custom Code
Analyst assignment based on training [URS 3]	Medium	A data integrity issue in this function could result in a lab analyst being assigned to run a lab test without proper training.	Low	Standard system functionality without modification
Testing charges for each product [URS 4]	Low	This function has no impact on patient safety or product quality.	High	Custom code

56



57



58

Risk Mitigation Definition

Risk Mitigation

Actions taken to reduce the risk




Validation Center™

Copyright © 2025, ProPharma Group

59

59

When does Risk Mitigation Take Place?



Validation Center™

Copyright © 2025, ProPharma Group

60

60

What are Risk Mitigation Activities?

Risk Mitigation Examples

Activities that reduce the likelihood of user errors:

- 2nd person verification of data entry
- Improved user training
- Design changes for error-prone features

Activities that increase the likelihood of detection of system issues before harm:

- Audit trail reviews
- Periodic checks of back-ups
- Access reviews

Activities that reduce the likelihood of system failure:

- Design reviews
- Code walkthroughs
- Testing



Validation Center™

Copyright © 2025, ProPharma Group

61

61

Mitigation during Design & Dev Stages

FDA Guidance General Principles of Software Validation
Software design specification should include software risk analysis.

ICH Q9 Quality Risk Management
Leverage Risk Assessment:
A. To select the design of computer hardware and software

PIC/S PI 011 Good Practices for Computerised Systems Used in Regulated "GXP" Environments
System Design & Development
Structural integrity and the application of good software and engineering practices are important for **critical** systems.
Extra benefits may be achieved by code walk-throughs including evaluation of **critical** algorithms and routines, prior to testing.
Risk reduction measures may need to be incorporated into the system's design and operation.



Validation Center™

Copyright © 2025, ProPharma Group

62

62

Mitigation during Design & Dev Stages



FDA Guidance Part 11, Electronic Records; Electronic Signatures – Scope and Application

Part 11 Approach: We [FDA] recommend that you base your approach [to part 11] on a justified and **documented risk assessment** and a determination of the potential of the system to impact product quality and safety, and record integrity.

FDA Guidance Part 11, Electronic Records; Electronic Signatures – Scope and Application

Audit Trails: We recommend that you base your decision on **whether or not to apply audit trails**, or other appropriate measures, on the need to apply with predicate rule requirements, a justified and **documented risk assessment**, and a determination of the potential effect on product quality and safety, and record integrity.


FDA Guidance Computerized Systems Used in Clinical Investigations

Audit Trails: The **need for audit trails** should be determined based on a justified and **documented risk assessment** that takes into consideration circumstances surrounding system use, the likelihood that information might be compromised, and any system vulnerabilities.

Validation Center™ Copyright © 2025, ProPharma Group 63

63

Mitigation during Vendor Selection



FDA Guidance General Principles of Software Validation

Vendor Audits: Depending upon the device **risk** involved, the device manufacturer should consider **auditing the vendor's design and development methodologies** used in the construction of the OTS software and should assess the development and validation documentation generated for the OTS software.

PIC/S PI 011 Good Practices for Computerised Systems Used in Regulated "GXP" Environments


Supplier Audits and Approval: The need to perform a **supplier audit** should be linked to the regulated user's **risk assessment** and quality assurance standards.

For GxP regulated applications it is essential for the regulated user to define a requirement specification prior to selection and to carry out a properly documented **supplier assessment** and **risk analysis** for the various system options. Information for such exercises may come from supplier audits and research into the supplier's product versions in the user community and literature.

Validation Center™ Copyright © 2025, ProPharma Group 64

64

Mitigation during Validation Planning



FDA Guidance General Principles of Software Validation 

Validation Planning: The quality plan should identify the role that risk (hazard) management will play.

Tracing: A software requirements traceability analysis should be conducted to trace software requirements to (and from) system requirements and the risk analysis results.

FDA Guidance General Principles of Software Validation


Validation Scope & Scale: Validation coverage should be based on the software's **complexity** and **safety risk**. The **selection of validation activities** should be commensurate with the **complexity** of the software design and the **risk** associated with use of the software for its specific intended use. As the **risk** increases, additional validation activities should be added to cover the additional **risk**.

For **very low risk** applications, certain tasks might not be needed at all.

 Validation Center™ Copyright © 2025, ProPharma Group  65

65

Mitigation during Validation Planning



PIC/S PI 011 Good Practices for Computerised Systems Used in Regulated "GXP" Environments

Validation scope should include GxP compliance criteria, ranked for all product/process quality and data integrity **risk criticality**, should the system fail or malfunction.

It is essential to assign priorities and attention to those systems (and features within systems) that represent **the highest potential for disaster**, should they malfunction or become inoperative.



ICH Q9 Quality Risk Management

Leverage Risk Assessment to determine the **extent of validation**, e.g.,

- identification of critical performance parameters
- selection of the requirements and design
- code review
- the extent of testing and test methods
- reliability of electronic records and signatures.



 Validation Center™ Copyright © 2025, ProPharma Group  66

66

Mitigation during and after Validation



FDA Guidance General Principles of Software Validation

Testing: The amount of structural testing should be commensurate with the level of **risk** posed by the software. The amount of path coverage is normally established based on the **risk or criticality** of the software under test.

Validation Evidence: Document requirements and **risk analysis** of the automated process help to define the scope of the evidence needed to show that the software is validated for its intended use.

FDA Guidance Computerized Systems Used in Clinical Investigations

Validation of Changes: The effects of changes to the system should be evaluated, and some should be validated depending on **risk**

Validation Center™ Copyright © 2025, ProPharma Group 67

67

Mitigation during the Life of the System

PIC/S PI 011 Good Practices for Computerised Systems Used in Regulated "GXP" Environments

Data Entry: Where applicable, there should be special procedures for **critical data entry** requiring and second check.

Back-Ups: The frequency of back-up is dependent on the computer system function and the **risk assessment** of the loss of data.

There should be procedures to assure routine back-up of data to a safe storage location, adequately separated from the primary storage location, and at a frequency based on the **analysis of risk** to GxP data.

FDA Guidance Part 11, Electronic Records; Electronic Signatures – Scope and Application


Record Maintenance: We [FDA] suggest that your decision on how to maintain records be based on predicate rule requirements and that you base your decision on a justified and **documented risk assessment** and a determination of the value of the records over time.

FDA Guidance Computerized Systems Used in Clinical Investigations


Security: We [FDA] recommend that passwords or other access keys be changed at established intervals commensurate with a **documented risk assessment**

Validation Center™ Copyright © 2025, ProPharma Group 68

68



69



70

Risk Based Approach to Validation Testing

Criticality	High	Med	Low	High	Med	Low	High	Med	Low
Complexity	High	High	High	Med	Med	Med	Low	Low	Low
Requirements Coverage	All requirements, multiple data sets	All requirements, single data set	Sampling	All requirements, multiple data sets	All requirements, single data set	Sampling	All requirements, single data set	All requirements, single data set	Sampling
Path testing	All paths, multiple scenarios	All paths, single scenario	Sampling	All paths, single scenario	All paths, single scenario	Sampling	All paths, single scenario	Sampling	Sampling
Boundary testing	✓	✓	Optional	✓	Optional	Optional	✓	Optional	Optional
Test case degree of detail and specificity	Specific, detailed	Medium detail	General	Specific, detailed	Medium detail	General	Specific, detailed	Medium detail	General
Test data similar to production data	✓	✓	Optional	✓	Optional	Optional	✓	Optional	Optional
Testing evidence	Completed protocol, Screen prints of test inputs and outputs	Completed protocol, Screen prints of test outputs	Completed protocol	Completed protocol, Screen prints of test inputs and outputs	Completed protocol, Screen prints of test outputs	Completed protocol	Completed protocol, Screen prints of test inputs and outputs	Completed protocol, Screen prints of test outputs	Completed protocol
User execution of validation tests	OQ & PQ	PQ	Optional	PQ	Optional	Optional	PQ	Optional	Optional

✓ Required

Validation Center™ Copyright © 2025, ProPharma Group 71

71

Risk Based Approach to Validation Documentation

Criticality	High	Med	Low	High	Med	Low	High	Med	Low
Complexity	High	High	High	Med	Med	Med	Low	Low	Low
Change Request	✓	✓	✓	✓	✓	✓	✓	✓	✓
Risk Assessment	✓	✓	✓	✓	✓	✓	✓	✓	✓
Validation Plan	✓	✓	Optional	✓	✓	Optional	✓	✓	Optional
User Requirements (URS)	✓	✓	Optional	✓	✓	Optional	✓	✓	Optional
Functional Specifications (FS)	Highly Detailed	Less Detail	Optional	Highly Detailed	Less Detail	Optional	Medium Detail	Less Detail	Optional
Design: Architecture	✓	✓	Optional	✓	✓	Optional	✓	✓	Optional
Design: Software	Highly Detailed	Less Detail	Optional	n/a	n/a	n/a	n/a	n/a	n/a
Design: Configuration	n/a	n/a	n/a	✓	✓	Optional	n/a	n/a	n/a
Test Plan/Design	✓	✓	Optional	✓	Optional	Optional	Optional	Optional	Optional
Validation Protocols (IQ, OQ, PQ)	✓	✓	Optional	✓	✓	Optional	✓	✓	Optional

✓ Required

Validation Center™ Copyright © 2025, ProPharma Group 72

72

Risk Based Approach to Validation Documentation

Criticality	High	Med	Low	High	Med	Low	High	Med	Low
Complexity	High	High	High	Med	Med	Med	Low	Low	Low
Validation Incident Reports	✓	✓	Optional	✓	✓	Optional	✓	✓	Optional
Trace Matrix – URS to FS	✓	✓	Optional	✓	✓	Optional	✓	✓	Optional
Trace Matrix – FS to Design	✓	✓	Optional	✓	Optional	Optional	Optional	Optional	Optional
Trace Matrix – URS to PQ	✓	✓	Optional	✓	✓	Optional	✓	✓	Optional
Trace Matrix – FS to OQ	✓	✓	Optional	✓	✓	Optional	✓	✓	Optional
OQ, PQ Trace To:	Test Step	Test Step	Optional	Test Step	Test Case	Optional	Test Step	Test Case	Optional
Validation Summary	✓	✓	Optional	✓	✓	Optional	✓	✓	Optional
Deployment Plan	✓	✓	Optional	✓	✓	Optional	✓	✓	Optional
Data Conversion Plan	✓	✓	Optional	✓	✓	Optional	✓	✓	Optional

✓ Required



Validation Center™

Copyright © 2025, ProPharma Group

73

73

Risk Based Approach to Verification Activities

Criticality	High	Med	Low	High	Med	Low	High	Med	Low
Complexity	High	High	High	Med	Med	Med	Low	Low	Low
Vendor Assessment	n/a	n/a	n/a	✓	✓	Optional	✓	✓	Optional
Unit Testing	✓	✓	Optional	n/a	n/a	n/a	n/a	n/a	n/a
Code Review	✓	✓	Optional	n/a	n/a	n/a	n/a	n/a	n/a
Design Review	✓	✓	Optional	✓	Optional	Optional	Optional	Optional	Optional
Part 11 Compliance Assessment	✓	✓	n/a	✓	✓	n/a	✓	✓	n/a
Verification of System Use and Support SOPs **	✓	✓	Optional	✓	✓	Optional	✓	✓	Optional

✓ Required

** System Use and Support SOPs include: Back-up, Recovery, Security and Access, Training Requirements, Incident Handling, Change Management, Technical Operation and Routine Maintenance, User Operation



Validation Center™

Copyright © 2025, ProPharma Group

74

74

Risk Based Validation Example

Examples from Laboratory Management System

	Function	Criticality	Technology	Complexity
A	Interface to a lab instrument to control instrument and read results	High	Configured using the out-of-the-box instrument interface screen	Medium
Document Requirements • User Requirements • Detailed Functional Specs • Design Documentation (Architecture + Configuration) • Test Plan/Design • Protocols (IQ, OQ, PQ) • Trace Matrices (URS → FS, FS → Design, URS → PQ, FS → OQ)		Testing Requirements • All requirements, multiple data sets • All paths, 1 scenario • Boundaries • Realistic test data • Screen prints of inputs and outputs • Users execute PQ; may delegate OQ execution		Additional Verifications • Design Review • Part 11 Compliance Assessment • SOPs for system use and support



Validation Center™

Copyright © 2025, ProPharma Group



75

75

Risk Based Validation Example

Examples from Laboratory Management System

	Function	Criticality	Technology	Complexity
B	Calculation of batch pass/fail based on lab test results	High	Custom code	High
Document Requirements • User Requirements • Detailed Functional Specs • Design Documentation (Architecture + Software) • Test Plan/Design • Protocols (IQ, OQ, PQ) • Trace Matrices (URS → FS, FS → Design, URS → PQ, FS → OQ) • Unit Test Report • Code Review Report		Testing Requirements • All requirements, multiple data sets • All paths, multiple scenarios • Boundaries • Realistic test data • Screen prints of inputs and outputs • Users execute both OQ and PQ		Additional Verifications • Design Review • Part 11 Compliance Assessment • SOPs for feature use • Unit Testing • Code Review



Validation Center™

Copyright © 2025, ProPharma Group



76

76

Risk Based Validation Example

Examples from Laboratory Management System

	Function	Criticality	Technology	Complexity
C	Entry of training dates	Medium	Out-of the box functionality	Low
Required Documents - User Requirements - Functional Specs (can be less detailed) - Design Documentation (Architecture only) - Protocols (IQ, OQ, PQ) - Trace Matrices (URS → FS, URS → PQ, FS → OQ) Optional Documents - Test Plan/Design - Trace from FS → Design Testing Requirements - All requirements, single data set - Sample of paths - Screen prints of outputs (no screen prints of inputs) Testing Options - Boundary testing - Realistic test data - Users may delegate both OQ & PQ execution Additional Verifications - Part 11 Compliance Assessment - SOPs for feature use Optional Verifications - Design Review				



Validation Center™

Copyright © 2025, ProPharma Group



77

77

Risk Based Validation Example

Examples from Laboratory Management System

	Function	Criticality	Technology	Complexity
D	Reporting of test charges for a department	Low	Custom report developed in house	High
Optional Documents - User Requirements - Functional Specs - Design Documentation - Test Plan - Protocols (IQ, OQ, PQ) - Trace Matrices - Unit Test Report - Code Review Report Testing Requirements - Sample of requirements - Sample of paths Testing Options - Boundary testing - Realistic test data - Screen prints - Users may delegate both OQ & PQ execution Optional Verifications - Part 11 Compliance Assessment - SOPs for feature use - Design Review - Code Review - Unit Testing				



Validation Center™

Copyright © 2025, ProPharma Group



78

78

Can we leverage the vendor's work?

Criticality	High	Med	Low	High	Med	Low	High	Med	Low
Complexity	High	High	High	Med	Med	Med	Low	Low	Low
Vendor Assessment	n/a	n/a	n/a	Required	Required	Optional	Required	Required	Optional
Unit Testing	Required	Required	Optional	n/a	n/a	n/a	n/a	n/a	n/a
Code Review	Required	Optional	Optional	n/a	n/a	n/a	n/a	n/a	n/a
Part 11 Compliance Assessment	Required	Required	Optional	Required	Required	Optional	Required	Required	Optional
Verification of System Use and Support SOPs **	Required	Required	Optional	Required	Required	Optional	Required	Required	Optional



Validation Center™

Copyright © 2025, ProPharma Group



79

79

Can we leverage the vendor's work?

Vendor Rating	Impact to Validation Approach
Full Approval	- Follow risk-based validation matrix - Internally review, approve vendor provided documents
Restricted Approval	- Use vendor documents with caution - Rating indicates increased risk, so additional validation required. - Approach validation as if 1 complexity level higher - If configured, approach as "custom" - If out-of-the-box, approach as "configured"
Not Approved	- Avoid reliance on vendor documents - Rating indicates increased risk, so additional validation required. - Approach validation as if "Custom"



Validation Center™

Copyright © 2025, ProPharma Group



80

80

Have You Ever Heard...

Computer System Validation is a waste of time

It's just a bunch of paperwork

It doesn't find the bugs

We just repeated everything the vendor already did

VC Validation Center™ Copyright © 2025, ProPharma Group 81

81

Risk Management Framework

Risk Management Process				
Risk Assessment	SOP System Risk Assessment			
	SOP Risk Based Validation	SOP Audit Trails	SOP Audit Trail Review	SOP Software Vendor Assessment
	SOP User Training	SOP Incident Management	SOP System Backup	SOP Business Continuity Etc.

VC Validation Center™ Copyright © 2025, ProPharma Group 82

82

Risk Mitigation in ...

Vendor Assessment SOP *example*

SOP Software Vendor Assessment	System Criticality Level	Vendor Assessment Method
	High	An audit is the preferred method for highly critical software applications.
	Medium	Questionnaire is the preferred method for medium criticality software applications.
	Low	Vendors of low criticality software applications do not require assessment.

83

Risk Mitigation in ...

Audit Trail SOP *example*

SOP Audit Trails	Require- ment Criticality Level	Audit Trail Requirement	Audit Trail Review
	High	Audit trail is <u>required</u> for records associated with highly critical system functions	At the time of record approval
	Medium	Audit trail is <u>required</u> for records associated with system functions of medium criticality	Periodically
	Low	Audit trail is <u>optional</u> for records associated with system functions of low criticality	Optional

84

Risk Mitigation in ...

Audit Trail Review SOP *example*

	Requirement Criticality Level	Review Timing	Audit Trail Review Scope	Audit Trail Reviewer
 SOP Audit Trail Review	High	During data review and approval	Comprehensive	Independent QA Reviewer
	Medium	Every 6-12 months	Targeted Scenarios	Business Process Owner
	Low	Not required	Targeted Scenarios	Business Process Owner



Validation Center™

Copyright © 2025, ProPharma Group



85

85

Risk Mitigation in ...

User Training SOP *example*

	Requirement Criticality Level	Training Format	
		Function is not intuitive to use correctly	Function is intuitive to use correctly
 SOP User Training	High	- Instructor Led Class - Hands-on Exercises - Competency Exam	- Self-study Materials - Hands-on Exercises - Competency Exam
	Medium	- Instructor Led Class - Hands-on Exercises	Self-study Materials
	Low	- Self-study Materials - Hands-on Exercises	Self-study Materials



Validation Center™

Copyright © 2025, ProPharma Group




86

86

Risk Mitigation in ...

System Back-up SOP *example*

	System Criticality Level	Back-up Location	Back-up Media Audit (Restoration Test) Frequency
 SOP System Back-Up	High	Off-Site Data Center in Separate Geographic Area	Annual
	Medium	Off-Site Data Center in Same Geographic Area	Every 18 months
	Low	Server Room in Separate Building	Not required



Validation Center™

Copyright © 2025, ProPharma Group



87

87

Risk Mitigation in ...

Business Continuity SOP *example*

	Requirement Criticality Level	Business Continuity Procedure (BCP) Required	BCP Testing
 SOP Business Continuity	High	Yes – Detailed	Annual
	Medium	Yes – Less Detailed	Every 2 Years
	Low	No	Not Required



Validation Center™

Copyright © 2025, ProPharma Group



88

88

Risk Mitigation in ...

Incident Management SOP *example*

		Resolution Priority		
		Users cannot perform job	Major Inconvenience	Minor Inconvenience
SOP Incident Management	Requirement Criticality Level			
	High	High	High	High
	Medium	High	Medium	Medium
	Low	High	Medium	Low

89



FDA Leadership By Example

Part 4

90

Part 4: FDA Leadership by Example

- Section Overview
 - Warning Letter Data
 - Warning Letter Examples



Validation Center™

Copyright © 2025, ProPharma Group

91

91

FDA Warning Letter Data

- Data Source
 - FDA Warning Letters related to Software and Computers
 - 3 Year Date Range: 2022 through 2024
- Summaries
 - By system type
 - By observation topic
 - By validation observation topics



Validation Center™

Copyright © 2025, ProPharma Group

92

92

FDA Warning Letter Example

Regulatory
Reference

Summary
Finding

2. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 C.F.R. §211.68(b)).

Your firm failed to have adequate procedures for the use of computerized systems in the quality control (QC) laboratory. Our inspection team found that current computer users in the laboratory were able to delete data from analyses. Notably, we also found that the audit trail function for the gas chromatograph (GC) and the X-Ray Diffraction (XRD) systems was disabled at the time of the inspection. Therefore, your firm lacks records for the acquisition, or modification, of laboratory data.

Moreover, greater than (b)(4) QC laboratory personnel shared (b)(4) login IDs for (b)(4) high performance liquid chromatographs (HPLC) units. In addition, your laboratory staff shared one login ID for the XRD unit. Analysts also shared the username and password for the Windows operating system for the (b)(4) GC workstations and no computer lock mechanism had been configured to prevent unauthorized access to the operating systems. Additionally, there was no procedure for the backup and protection of data on the GC standalone workstations.

Specific
Observations



Validation Center™

Copyright © 2025, ProPharma Group




93

93

Software & Computer Warning Letters

3 Year Citation Summary by System Type



"Other" system types include systems for IRB, Calibration Management, Issue Management, Product Design, Environmental Monitoring, Stability, CoA, and Audit Management



Validation Center™

Copyright © 2025, ProPharma Group




94

94

Software & Computer Warning Letters

3 Year Citation Summary by Observation Topic



*"Other" observation topics include Risk Management, IT Vendor Management, Critical Defects, Change Control, System Documentation, CAPAs for device software issues, FDA registration of device software



Validation Center™


Copyright © 2025, ProPharma Group

95

95

Software & Computer Warning Letters

3 Year Citation Summary by Validation Issue



Validation Center™


Copyright © 2025, ProPharma Group

96

96

Software & Computer Warning Letters

3 Year Citation Summary by Validation Issue



97

Warning Letter Examples

Regulatory Reference	21 CFR 820 (Medical Devices)
System Type	Medical Device Software
FDA Branch or District	CDRH

Failure to adequately establish and maintain procedures to control the design to ensure that requirements are met.

- *Development of Key Functionality*, requires the firm to assess risk and re-assess risk as needed. Although XXXXXX was released on November 25, Software Risk Management Summary Doc. was not completed until July 14, and did not include an analysis of the risk specific to the intended use of XXXXXX.

98

Warning Letter Examples

Regulatory Reference	21 CFR 820 (Medical Devices)
System Type	Medical Device Software
FDA Branch or District	Cincinnati District

Failure to demonstrate that the device was developed in accordance with the design control requirements of the Quality System regulation.

- Failure to have complete risk analyses in that 5 versions of risk analysis were not controlled documents.
- Risk analyses were not reviewed and approved.
- Risk analyses were not updated when a software issue was discovered that resulted in a software change.



Validation Center™

Copyright © 2025, ProPharma Group

99

99

Warning Letter Examples

Regulatory Reference	21 CFR 820 (Medical Devices)
System Type	Medical Device Software
FDA Branch or District	Florida District

Failure to adequately establish and maintain procedures for validation.

- Firm's Risk Analysis Report for software version 00, does not adequately assess the risk presented by the software controlling the X-Ray Unit XXX as a moderate risk to users and patients.
- For example, the report indicates a "No" to the questions:
 - "Could a malfunction of, or a latent design flaw in the Software Device lead to an erroneous diagnosis or a delay in delivery of appropriate medical care that would likely lead to Moderate Injury?"
 - "Does the Software Device control the delivery of potentially harmful energy that could result in death or serious injury?"



Validation Center™

Copyright © 2025, ProPharma Group

100

100



Conclusion

Photo: iStockphoto.com/istockphoto.com CC BY-SA
Validation Center™ Copyright © 2025, ProPharma Group 101

101

Next Steps



1. Review your regulations and guidelines
2. Identify your criticality levels and definitions
3. Define your complexity measures
4. Determine how you will apply complexity & criticality to validation and software quality practices
5. Write your policies and procedures
6. Train your staff

Validation Center™ Copyright © 2025, ProPharma Group 102

102

Need Help?



ValidationCenter.com Library of SOPs and Template



Online and Classroom CSV Training



Software QA and Validation Program Implementation
Validation Services



Audit Readiness Assessments



Validation Center™

Copyright © 2025, ProPharma Group

103

103

Thank You!

Thanks for your interest in Risk Based Approach to
Software Quality & Validation.

Any questions about what we have discussed today?

Please, feel free to contact me:

Deb Bartel

Deb.Bartel@ProPharmaGroup.com

ValidationCenter.com

Follow us!



Validation Center™

Copyright © 2025, ProPharma Group

104

104